Skip to main content
SpringerLink
Log in

Long-Term Survival After Diagnosis of Hepatic Metastatic VIPoma (Report of Two Cases with Disparate Courses and Review of Therapeutic Options)

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

This report describes two patients withpancreatic cholera caused by vasoactive intestinalpolypeptide (VIP)-producing tumors, which originated inthe pancreas and showed metastases in both hepatic lobes at time of diagnosis. However, the two tumorsdisplayed remarkably disparate clinical courses. Due tothe protracted but progressive course over more than 10years, a multifaceted therapeutic approach was performed to control symptoms and to improvequality of life. The long-acting somatostatin analogoctreotide was the most effective treatment forrelieving symptoms and correcting fluid and electrolytes disturbances. The effects of complementarytreatments, including systemic chemotherapy andhyperselective chemoembolization, as well as concurrentapplication of octreotide and prednisolone or interferon with respect to clinical symptoms, VIP levels,and tumor growth are reviewed. Our experience, althoughsmall, emphasizes the need for an expert, well-planned,adaptive, and multidisciplinary approach in the care of these complex patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Verner JV, Morrison AB: Isletce ll tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 9:374–380, 1958

    Google Scholar 

  2. Modlin IM, Lewis JJ, Ahlmann H, Bilchik AJ, Kumar RR: Management of unre sectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 176:507–518, 1993

    Google Scholar 

  3. Feldman JM: Carcinoid tumors and syndrome. Sem Oncol 14:237–246, 1987

    Google Scholar 

  4. Leavey SF, Holloway H, Courtney MG, Lane BE, Royston D, Buchanan KD, Fielding JF: Pancreatic VIPomas: Spectrum of presentation and evolution of diagnostic and therapeutic modalities. Ir J Med Sci 164:37–39, 1995

    Google Scholar 

  5. Grama D, Eriksson B, Martensson H, Cedermark B, Ahren B, Kristoffersson A, Rastad J, Oberg K, Akerstrom G: Clinical characteristics, treatment and survival in patients with pancre-atic tumors causing hormonal syndromes. World J Surg 16:632–639, 1992

    Google Scholar 

  6. Woussen-Colle MC, Lingier P, Vertongen P, Vandermers-Piret MC, Vandermeers A, Robberecht P: Chromogranin A(210-301) is the major form of pancreastatin-like mate rial in human gut extracts and endocrine tumors. Peptides 15:869–874, 1994

    Google Scholar 

  7. Zimmer TH, Ziegler K, Bader M: Localisation of neuroendocrine tumors of the upper gastrointestinal tract. Gut 35:471–475, 1994

    Google Scholar 

  8. Kvols LK, Reubi JC: Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 32:197–201, 1993

    Google Scholar 

  9. Arnold R, Frank M, Kajdan U: Management of gastroente ropancre atic endocrine tumors: the place of somatostatin analogues. Digestion 55(suppl 3):107–113, 1994

    Google Scholar 

  10. Debas HT, Gittes G: Somatostatin analogue in functioning neuroendocrine gut tumors. Digestion 54(suppl 1):68–71, 1993

    Google Scholar 

  11. Eriksson B, berg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208, 1993

    Google Scholar 

  12. Koelz A, Kraenzlin M, Gyr K, Meier V, Bloom SR, Heitz P, Stalder H: Escape of the response to a long-acting somatostatin analogue (SNIS 201-995) in patients with VIPoma. Gastroenterology 92:527–531, 1987

    Google Scholar 

  13. Lamberts SW, Pieters GF, Metselaar HJ, Ong GL, Tan HS, Reubi JC: Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol 119:561–566, 1988

    Google Scholar 

  14. Harris AG, O'Dorisio TM, Woltering EA, Anthony LB, Burton FR, Geller RB, Grendell JH, Levin B, Redfern JS: Consensus statement: Octreotide dose titration in se cre tory diarrhea. Dig Dis Sci 40:1464–1473, 1995

    Google Scholar 

  15. Niitsu Y, Goto Y, Maeda M, et al: Successful treatment of a VIPoma by continuous subcutaneous infusion of somatostatin analogue (SMS 201-995). Aliment Pharmacol Ther 2:269–279, 1988

    Google Scholar 

  16. Scherübl H, Wiedenmann B, Riecken EO, Thomas F, Böhme E, Räth U: Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 30A:1591–1592, 1994

    Google Scholar 

  17. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM: Islet cell carcinomas of the pancreas: A twenty-ye ar experience. Surgery 104:1011–1017, 1988

    Google Scholar 

  18. Rothmund M, Stinner B, Arnold R: Endocrine pancreatic carcinoma. Eur J Surg Oncol 17:191–199, 1991

    Google Scholar 

  19. Grier JF: WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: Clinical feature, diagnosis and treatment. South Med J 88:22–24, 1995

    Google Scholar 

  20. Rood RP, DeLellis RA, Dayal Y, Donowitz M: Pancreatic cholera syndrome due to a vasoactive intestinal polypeptideproducing tumor: Further insights into the pathophysiology. Gastroenterology 94:813–818, 1988

    Google Scholar 

  21. Makowka L, Tzakis AG, Mazzaferro V, et al: Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg GynecolObstet 68:107–111, 1989

    Google Scholar 

  22. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, Ringe B, Pichlmayr R: Liver transplantation for me tastatic neuroendocrine tumors. Ann Surg 225:347–354,1997

    Google Scholar 

  23. Bechstein W, Neuhaus P: Liver transplantation for hepatic me tastases of neuroendocrine tumors. Ann NY Acad Sci 733:507–514, 1994

    Google Scholar 

  24. Broder LE, Carter SK: Pancreatic isletcell carcinoma. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108–118, 1973

    Google Scholar 

  25. Altimari AF, Badrinath K, Reisel HJ, Prinz RA: DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 102:1009–1017, 1987

    Google Scholar 

  26. Moertel CH, Lavin PT, Hahn RG: Phase II trial of doxorubicin therapy for advance d islet-cell carcinoma. Cancer Treat Rep 66:1567–1569, 1982

    Google Scholar 

  27. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozotocin-doxorubicin, streptozotocin-5-fluorouracil, or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 326:519–523, 1992

    Google Scholar 

  28. Eriksson B, Oberg K, Alm G, Karlsson A, Lundqvist G, Andersson T, Wilander E, Wide L: Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon. Lancet 2:1307–1309, 1986

    Google Scholar 

  29. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L: Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian trials in medical oncology group. Cancer 72:3099–3015,1993

    Google Scholar 

  30. Nold R, Frank M, Kajdan U, Trost U, Klose KJ, Arnold R: Kombinierte Behandlung metastaiserter endokriner Tumoren des Gastrointestinaltrakts mit Octreotid und Interferon-Alpha.Z Gastroenterol 32:193–197, 1994

    Google Scholar 

  31. Öberg K: Interferon-alpha versus somatostatin or the combination of both in gastroenterpancreatic tumours. Digestion 57( suppl 1):81–83, 1996

    Google Scholar 

  32. Juhlin C, Papanicolaou V, Arnberg H, Klareskog L, Lorelius LE, Rastad J, Oberg K, Akerstrom G: Clinical and biochemical effects in vivo of monoclonal antitumor antibody in Verne r-Morrison' s syndrome. Cancer 73:1346–1352, 1994

    Google Scholar 

  33. Antonelli A, Gambuzza C, Betoni F, Baschieri L: Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome. J Endocrinol Invest 16:57–59, 1993

    Google Scholar 

  34. Valette PJ, Souquet JC: Pancreaticislet cell tumors metastatic to the liver: Treatment by hepaticartery chemo-embolization. Horm Res 32:77–79, 1989

    Google Scholar 

  35. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M: Hepatic arterial chemoembolisation in patients with liver metastases of endocrine tumors. Cancer 71:2624–2630, 1993

    Google Scholar 

  36. Clouse ME, Perry L, Stuart K, Sokes KR: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55( suppl 3):92–97, 1994

    Google Scholar 

  37. Ajani JA, Carrasco CH, Wallace S: Neuroendocrine tumors me tastatic to the liver. Vascular occlusion therapy. Ann NY Acad Sci 733:479–487, 1994

    Google Scholar 

Download references

Authors
  1. Huan N. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berthold Backes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Lammert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joachim Wildberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ron Winograd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Norbert Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Heinz Rieband
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Siegfried Matern
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nguyen, H.N., Backes, B., Lammert, F. et al. Long-Term Survival After Diagnosis of Hepatic Metastatic VIPoma (Report of Two Cases with Disparate Courses and Review of Therapeutic Options). Dig Dis Sci 44, 1148–1155 (1999). https://doi.org/10.1023/A:1026672022917

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026672022917

Search

Navigation